Business
Preliminary results for the year ended 31 Dec 2024
Preliminary results for the year ended 31 Dec 2024.
About this update from Eden Research Plc
[{"type":"text","content":"\n\n6 May 2025\n \nEden Research\n \n(\"Eden\" or \"the Company\")\n \nPreliminary results for the year ended 31 December 2024\n \nEden Research (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, announces its preliminary results for the year ended 31 December 2024.\n \nCommercial and operational highlights\n· Authorisation for Mevalone® received in the key US state of California in January 2024.\n· Mevalone® authorised for use in new crops and fungal pathogens in Spain in June 2024.\n· Authorisation for Mevalone® received in Germany and Czechia (post period-end).\n· More than 140 insecticide field trials were run in 2024 by Eden and potential distribution partners, following significant interest in the evaluation of Eden's development insecticide.\n· Strengthening of the Commercial Team with the appointment of a skilled team filling roles such as Commercial Lead, Product Management and Marketing Lead and Supply Chain Lead.\n· Eden named ESG Company of the Year at the prestigious 2024 Small Cap Network Awards in recognition of its commitment to environmental, social and governance matters and contribution to the green economy.\n \nFinancial highlights\n· Revenue for the year grew to £4.3 million (2023: £3.2 million), reflecting a growth rate of 34% year-over-year.\n· Operating loss for the year was £2.2 million (2023: £1.9 million)\n· Cash position at the year-end was £3.7 million (2023: £7.4 million)\n \nThe Group's full Financial Statements are available at: www.edenresearch.com.\n \nLykele van der Broek, Chairman of Eden Research plc, commented:\n \n\"Eden has seen another strong year of growth with overall revenue up 34% and product sales also up by a similar amount.\n \nIn addition to this, several key milestones were reached in 2024 which will all help to drive revenue in the short and medium term and get Eden to the point of cashflow positivity, which will be a significant milestone for the business.\n \nI remain very optimistic about Eden's prospects and believe that the Company is making excellent progress toward achieving its goal of becoming a ...